Morning Movers: Bloom Energy surges following $5B investment from Brookfield

A volatile weekend in trade relations and tactical messaging is fueling renewed market caution, though stock futures are rebounding after a sharp drop late last week, helped by a softer tone from President Trump on U.S.-China tariffs. The pivot in rhetoric is being read as a tentative signal that escalation may moderate, which is offering relief to skittish investors.

Gold surged to fresh records above $4,070 per ounce as capital flows into safe havens intensify amid geopolitical and policy uncertainty. Silver also climbed to an all-time high.

In the oil patch, prices are attempting a rebound after recent weakness. Brent and WTI both climbed after hitting five-month lows, with hopes that U.S.-China dialogue and easing trade tensions might cushion global demand concerns.

The dollar steadied after earlier selling pressure, as markets calibrated between the risks of a fresh tariff war and the possibility of renewed diplomatic overtures.

In pre-market trading, S&P 500 futures rose 1.21%, Nasdaq futures rose 1.74% and Dow futures rose 0.89%.

Check out this morning’s top movers from around Wall Street, compiled by The Fly.

HIGHER –

• Bloom Energy (BE) and Brookfield Asset Management (BAM) up 26% and 2%, respectively, after the companies announced a $5B partnership to implement “a reimagined future for AI infrastructure”
• Dragonfly Energy (DFLI) up 12% after reporting preliminary third quarter results
• Warner Bros. Discovery (WBD) up 4% after Bloomberg reported the company rejected Paramount Skydance’s (PSKY) initial takeover offer of around $20 per share for being too low
• Blackstone (BX) up 1% after agreeing to sell a portfolio of UK warehouses valued at GBP 1B to Tritax Big Box REIT (TTBXF)
• Bright Scholar (BEDU) up 1% after entering into an agreement and plan of merger with Excellence Education Investment and Bright Education Mergersub

DOWN AFTER EARNINGS –

• Fastenal (FAST) down 4%

LOWER –

• Tvardi Therapeutics (TVRD) down 86% after not observing a benefit in the REVERT clinical trial of TTI-101